Use of monoamine oxidase inhibitors in chronic neurodegeneration

References

• Fox HH. The chemical approach to the control of tuberculosis. Science. 1952;116:129–134.
   PubMed Web of Science ®Google Scholar
• Anonymous. New drugs for depression. Br Med J. 1960;1:178–179.
   PubMedGoogle Scholar
• Riederer P, Laux G. MAO-inhibitors in Parkinson’s disease. Exp Neurobiol. 2011;20:1–17.
   PubMedGoogle Scholar
• Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem. 2004;11:2033–2043.
   PubMed Web of Science ®Google Scholar
• Teo KC, Ho SL. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease. Transl Neurodegener. 2013;2:19.
   PubMedGoogle Scholar
• Bartl J, Muller T, Grunblatt E, et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm. 2014;121:379–383.
   PubMed Web of Science ®Google Scholar
• Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. 2004;65:1520–1524.
   PubMed Web of Science ®Google Scholar
• Tabi T, Szoko E, Vecsei L, et al. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2013;9:629–636.
   PubMed Web of Science ®Google Scholar
• Muller T, Hoffmann JA, Dimpfel W, et al. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm. 2013;120:761–765.
   PubMed Web of Science ®Google Scholar
• Ravikumar K, Sridhar B. Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. Acta Crystallogr C. 2010;66:o317–o320.
   Google Scholar
• Muller T. Emerging approaches in Parkinson’s disease - adjunctive role of safinamide. Ther Clin Risk Manag. 2016;12:1151–1160.
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Pawelec C, Roux S, et al. Discrimination of the amphetamine cue. Effects of A, B and mixed type inhibitors of monoamine oxidase. Neuropharmacology. 1984;23:569–573.
   PubMed Web of Science ®Google Scholar
• Song MS, Matveychuk D, MacKenzie EM, et al. An update on amine oxidase inhibitors: multifaceted drugs. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:118–124.
   PubMed Web of Science ®Google Scholar
• Konradi C, Riederer P, Jellinger K, et al. Cellular action of MAO inhibitors. J Neural Transm Suppl. 1987;25:15–25.
   PubMedGoogle Scholar
• Maruyama W, Dostert P, Matsubara K, et al. N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Radic Biol Med. 1995;19:67–75.
   PubMed Web of Science ®Google Scholar
• Naoi M, Matsuura S, Takahashi T, et al. A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun. 1989;161:1213–1219.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Li SW, Chung HD, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology. 2004;25:101–115.
   PubMed Web of Science ®Google Scholar
• Burke WJ, Kumar VB, Pandey N, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115:193–203.
   PubMed Web of Science ®Google Scholar
• Panneton WM, Kumar VB, Gan Q, et al. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One. 2010;5:e15251.
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, et al. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Faseb J. 2005;19:1899–1901.
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, et al. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci. 2007;1122:155–168.
   PubMed Web of Science ®Google Scholar
• Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem. 2002;82:913–923.
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007;103:500–508.
   PubMed Web of Science ®Google Scholar
• Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci. 2001;939:320–329.
   PubMed Web of Science ®Google Scholar
• Maruyama W, Yamamoto T, Kitani K, et al. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116:181–191.
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H, et al. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J Neural Transm Suppl. 2007;72:121–131.
   PubMedGoogle Scholar
• Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J Neural Transm. 2013;120:1539–1551.
   PubMed Web of Science ®Google Scholar
• Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105–108.
   PubMed Web of Science ®Google Scholar
• Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J Neural Transm (Vienna). 2016;123:91–106.
   PubMed Web of Science ®Google Scholar
• Gerlach M, Riederer P. Monoamin-oxidase-hemmer in: neuro-psychopharmaka. Vol. 2, eds, Riederer P, Laux G, Pöldinger W. Vienna: Springer; 2002. 437–557.
   Google Scholar
• Apud JA, Mattay V, Chen J, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32:1011–1020.
   PubMed Web of Science ®Google Scholar
• Fava M, Rosenbaum JF, Kolsky AR, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999;19:329–335.
   PubMed Web of Science ®Google Scholar
• Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol. 1994;5:344–350.
   PubMed Web of Science ®Google Scholar
• Lapish CC, Ahn S, Evangelista LM, et al. Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology (Berl). 2009;202:521–530.
   PubMed Web of Science ®Google Scholar
• Harris DS, Everhart T, Jacob P III, et al. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. BMC Clin Pharmacol. 2009;9:13–18.
   PubMedGoogle Scholar
• Yasar S, Gaal J, Panlilio LV, et al. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology (Berl). 2006;183:413–421.
   PubMed Web of Science ®Google Scholar
• Laux G, Riederer P, Müller U. Klinik/Indikationen in: neuro-psychopharmaka. Vol. 2, eds, Riederer P, Laux G, Pöldinger W. Vienna: Springer 2002. 489–507.
   Google Scholar
• Bieck PR. Interaktionen in: neuro-psychopharmaka. Vol. 2, eds, Riederer P, Laux G, Pöldinger W. Vienna: Springer 2002. 518–538.
   Google Scholar
• Da PM, Kettler R, Keller HH, et al. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl. 1989;28:5–20.
   PubMedGoogle Scholar
• Cattaneo C, Caccia C, Marzo A. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. et al. Clin Neuropharmacol. 2003;26:213–217.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Wilkinson JR. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol. 2012;52:620–628.
   PubMed Web of Science ®Google Scholar
• Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. 2011;26:766–767.
   PubMed Web of Science ®Google Scholar
• Magyar K, Szatmary I, Szebeni G, et al. Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. J Neural Transm Suppl. 2007;72:165–173.
   PubMedGoogle Scholar
• Magyar K. The pharmacology of selegiline. Int Rev Neurobiol. 2011;100:65–84.
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Logan J, et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 2001;68:2759–2768.
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs. 2012;72:643–669.
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr Top Med Chem. 2012;12:2177–2188.
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother. 2013;13:671–684.
   PubMed Web of Science ®Google Scholar
• Berg D, Godau J, Seppi K, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol. 2013;20:102–108.
   PubMed Web of Science ®Google Scholar
• Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111:201–216.
   PubMed Web of Science ®Google Scholar
• Laux G. Do MAO-B inhibitors have any role in the treatment of depression ? In: Szelenyi I, ed. Inhibitors of monoamine oxidase B. Pharmacology and clinical use in neurodegenerative disorders. Boston, Berlin: Birkhäuser Basel; 1993. p. 319–326.
   Google Scholar
• Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22:1184–1191.
   PubMed Web of Science ®Google Scholar
• Burke WJ. Mao-B inhibitor know-how: back to the pharm. Neurology. 2009;73:2048.
   PubMed Web of Science ®Google Scholar
• Lewitt PA. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. Clin Neuropharmacol. 2007;30:305–307.
   PubMed Web of Science ®Google Scholar
• Muller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718.
   PubMed Web of Science ®Google Scholar
• Michel TM, Kasbauer L, Gsell W, et al. Aldehyde dehydrogenase 2 in sporadic Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S68–S72.
   Google Scholar
• Laine K, Anttila M, Heinonen E, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol. 1997;20:419–433.
   PubMed Web of Science ®Google Scholar
• Lee HM, Koh SB. Many faces of Parkinson’s disease: non-motor symptoms of Parkinson’s disease. J Mov Disord. 2015;8:92–97.
   PubMedGoogle Scholar
• Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5:681–697.
   PubMedGoogle Scholar
• Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis. 2011;32:82–88.
   PubMed Web of Science ®Google Scholar
• Miller JW, Shukitt-Hale B, Villalobos-Molina R, et al. Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 1997;20:55–66.
   PubMed Web of Science ®Google Scholar
• Sian-Hulsmann J, Mandel S, Youdim MB, et al. The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem. 2011;118:939–957.
   PubMed Web of Science ®Google Scholar
• Sian-Hulsmann J, Monoranu C, Strobel S, et al. Lewy bodies: a spectator or salient killer? CNS Neurol Disord Drug Targets. 2015;14:947–955.
   PubMed Web of Science ®Google Scholar
• Muller T, Trommer I, Muhlack S, et al. Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm (Vienna). 2016;123:401–406.
   PubMed Web of Science ®Google Scholar
• Sabens EA, Distler AM, Mieyal JJ. Levodopa deactivates enzymes that regulate thiol-disulfide homeostasis and promotes neuronal cell death - implications for therapy of Parkinson’s disease. Biochemistry. 2010;49:2715–2724.
   PubMed Web of Science ®Google Scholar
• Przuntek H, Conrad B, Dichgans J, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 1999;6:141–150.
   PubMed Web of Science ®Google Scholar
• Gulyas B, Pavlova E, Kasa P, et al. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58:60–68.
   PubMed Web of Science ®Google Scholar
• Inaba-Hasegawa K, Akao Y, Maruyama W, et al. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J Neural Transm. 2013;120:435–444.
   PubMed Web of Science ®Google Scholar
• Muller T, Mannel M, Murck H, et al. Treatment of somatoform disorders with St. John’s wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med. 2004;66:538–547.
   PubMed Web of Science ®Google Scholar